Pegloticase + Methotrexate (MTX)
ApprovedCompleted 0 watching 0 views this week🔥 Hot
84
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Uncontrolled Gout
Conditions
Uncontrolled Gout
Trial Timeline
Mar 8, 2021 → Apr 24, 2023
NCT ID
NCT04772313About Pegloticase + Methotrexate (MTX)
Pegloticase + Methotrexate (MTX) is a approved stage product being developed by Amgen for Uncontrolled Gout. The current trial status is completed. This product is registered under clinical trial identifier NCT04772313. Target conditions include Uncontrolled Gout.
Hype Score Breakdown
Clinical
30
Activity
20
Company
9
Novelty
10
Community
12
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04772313 | Approved | Completed |
| NCT04762498 | Approved | Completed |
Competing Products
17 competing products in Uncontrolled Gout
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| KHK4563 + KHK4563 + KHK4563 + Placebo | Kyowa Kirin | Phase 2 | 52 |
| HR17031 injection + insulin glargine | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| Baxdrostat + Placebo | AstraZeneca | Phase 3 | 77 |
| Tralokinumab | AstraZeneca | Phase 3 | 77 |
| Baxdrostat + Placebo | AstraZeneca | Phase 3 | 77 |
| Benralizumab | AstraZeneca | Phase 3 | 77 |
| Baxdrostat + Placebo | AstraZeneca | Phase 2 | 52 |
| Experimental: Tralokinumab | AstraZeneca | Phase 3 | 77 |
| Phase IIb formulation + Putative phase III formulation + Slow dissolution variant 1 + Slow dissolution variant 2 + Test treatment E | AstraZeneca | Phase 1 | 33 |
| CIN-107 + Placebo | AstraZeneca | Phase 2 | 52 |
| Pegloticase | Amgen | Approved | 84 |
| Pegloticase + Methotrexate | Amgen | Phase 3 | 76 |
| Pegloticase + Methotrexate (MTX) | Amgen | Approved | 84 |
| Pegloticase with MTX | Amgen | Approved | 84 |
| abrocitinib | Pfizer | Pre-clinical | 22 |
| REGN5381 + Placebo | Regeneron Pharmaceuticals | Phase 2 | 51 |
| SAL0140 + SAL0140 placebo | Shenzhen Salubris Pharmaceuticals | Phase 1 | 32 |